Latest Content

A 1-time dose of arlo-cel demonstrated safety and efficacy in patients with relapsed or refractory multiple myeloma that was previously treated.

Learn the critical factors in determining prophylaxis for venous thromboembolism, a frequent and serious complication for patients with cancer.

Following imlunestrant’s approval, Komal Jhaveri, MD, FACP, compares the oral SERD to its counterpart, elacestrant, in terms of composition and trials.

AI-driven decision support can ease oncologists’ workloads and streamline care without reducing autonomy.

The FDA has granted approval to adjuvant cemiplimab treatment for patients with high-risk cutaneous squamous cell carcinoma after surgery and radiation.

CRS and ICANS were observed in 48% and 16%, respectively, of patients with ES-SCLC who received tarlatamab, according to real-world data.

A network to connect patients with unused medications with patients in need brought $18 million of free cancer medication while reducing drug waste.

In the phase 3 SURPASS-ET trial, ropeginterferon alfa-2b outperformed anagrelide as second-line therapy for high-risk essential thrombocythemia.

Cassie A. Gray, MS, RN, OCN, CHPN, explains how early palliative care integration benefits patients with advanced cancer.

The FDA has approved lurbinectedin plus atezolizumab for the treatment of extensive-stage small cell lung cancer following induction therapy with atezolizumab.

Jeneth Aquino, DNP, FNP-BC, explains that using ctDNA to guide a patient’s next steps can provide clarity in the treatment process.

The addition of atezolizumab to chemoradiation led to meaningful improvements to quality of life for patients with small cell lung cancer.

Heather Jackson, PhD, APRN, FNP-BC, NEA-BC, FAA-NP, explains the utility of a holistic approach to oncology care.